Voriconazole associated mucormycosis in a patient with relapsed acute lymphoblastic leukemia and hematopoietic stem cell transplant failure: A case report

J Mycol Med. 2018 Sep;28(3):527-530. doi: 10.1016/j.mycmed.2018.05.008. Epub 2018 May 26.

Abstract

The patients with hematologic malignancies and hematopoietic stem cell transplantation (HSCT) recipients are at high risk for invasive fungal diseases (IFDs) mainly due to the severe and prolonged neutropenia related to high-dose chemotherapy. Voriconazole prophylaxis is recommended for possible IFDs. Mucormycosis is a fulminant infection, which may occur after voriconazole prophylaxis for invasive aspergillosis in immunocompromised hosts. Here, we report mucormycosis after 4 months of voriconazole prophylaxis in a young patient with relapsed acute lymphoblastic leukemia and hematopoietic stem cell transplant failure and discuss the clinical manifestation, imaging, laboratory findings and therapeutic regimens. Clinician's awareness of this entity and timely diagnosis using conventional and molecular methods are the promising approach for the management of this devastating infection.

Keywords: Acute lymphoblastic leukemia; Hematopoietic stem cell transplantation recipients; Invasive fungal disease; Mucormycosis; Prophylaxis; Voriconazole; Zygomycosis.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunocompromised Host*
  • Male
  • Mucormycosis / chemically induced*
  • Mucormycosis / diagnosis
  • Mucormycosis / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Recurrence
  • Treatment Failure
  • Voriconazole / adverse effects*

Substances

  • Voriconazole